Lipocalin-2: Development, Analytical Characterization, and Clinical Testing of a New ELISA

Abstract

Lipocalin-2 (also known as neutrophil gelatinase-associated lipocalin [NGAL]) has been described as a promising marker of metabolic syndrome associated with inflammation. The aim of our work was to develop an assay for the determination of lipocalin-2 in human serum and to investigate its levels in healthy volunteers and donors suffering from metabolic syndrome. We also conducted a pilot study on individuals with metabolic syndrome and on healthy probands and measured lipocalin-2 in these individuals. We developed and evaluated the sandwich ELISA method for the quantitative determination of human lipocalin-2 in serum samples. We measured blood pressure, waist circumference, serum cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, insulin, glucose, creatinine, hs-CRP, and adiponectin and calculated the BMI and Quicki insulin sensitivity index. In the study on 153 healthy volunteers, we showed that sex and age are not determinative for lipocalin-2 serum values. Furthermore, we tested 45 individuals with metabolic syndrome; values of lipocalin-2 did not differ (78.8 vs. 80.0 μg/l, p=0.56) from the data of healthy individuals from the first study. Neither group differed with regard to sex or age. Lipocalin-2 correlated with alanine aminotransferase (ALT) (r=-0.3, p<0.01) aspartate aminotransferase (AST) (r=-0.3, p<0.01), cholesterol (r=-0.21, p=0.047), creatinine (r=0.19, p=0.05), and high-sensitivity C-reactive protein (hs-CRP) (r=0.22, p=0.036). No significant correlation was found between serum lipocalin-2 and BMI, waist circumference, blood pressure, triglycerides, HDL, Quicki, or the number of metabolic syndrome components. When study patients with metabolic syndrome were further stratified according to the number of components of metabolic syndrome, serum concentrations of lipocalin-2 did not differ. The results presented demonstrate the analytical competence of the lipocalin-2 assay. However, we assumed that lipocalin-2 is not a routinely usable marker of metabolic syndrome or obesity. The association between serum lipocalin-2 and obesity or metabolic syndrome was not validated in our study.

Key words

lipocalin-2 - ELISA - metabolic syndrome - glucose and lipid homeostasis - diabetes mellitus

References

• 1 Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, Fong HEH, Cheung CC, Mak TW. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury.  Proc Natl Acad Sci USA. 2006;  103 1834-1839
• 2 Flo TH, Smith KD, Rodriguez DJ, Holmes MA, Strong RK. Lipocalin 2 mediates an immune response to bacterial infection by sequestrating iron.  Nature. 2004;  432 917-921
• 3 Lin HH, Li WW, Lee YC, Chu ST. Apoptosis induced by uterine 24p3 protein in endometrial carcinoma cell line.  Toxicology. 2007;  234 203-215
• 4 Miharada K, Hiroyama T, Sudo K, Nagasawa T, Nakamura Y. Lipocalin 2 functions as a negative regulator of red blood cell production in an autocrine fashion.  FASEB J. 2005;  19 1881-1883
• 5 Dam RM van, Hu FB. Lipocalins and insulin resistance: etiological role of retinol-binding protein 4 and Lipocalin-2.  Clin Chem. 2007;  53 5-7
• 6 Wang Y, Lam KSL, Kraegen EW, Sweenery G, Zhang J, Tso AWK, Chow WS, Wat NMS, Xu JY, Hoo RCL, Xu A. Lipocalin-2 an inflammatory marker closely associated with obesity, insulin resistance and hyperglycemia in humans.  Clin Chem. 2007;  53 34-41
• 7 Poledne R, Valenta Z, Pit'ha J. CRP: a marker of a pro-inflammatory state and cardiovascular risk.  Vnitr Lek. 2007;  53 391-395
• 8 Nyström T. C-reactive protein: a marker or a player?.  Clin Sci (Lond). 2007;  113 79-81
• 9 Lorenz MW, Karbstein P, Markus HS, Sitzer M. High-sensitivity C-reactive protein is not associated with carotid intima-media progression: the carotid atherosclerosis progression study.  Stroke. 2007;  38 1774-1779
• 10 Grundy SM, Chair , Cleeman CHJI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.  Circulation. 2005;  112 2735

Correspondence